CRISPR Screen Reveals New Target to Boost Regulatory T Cell Therapy for Autoimmune Disease
Scientists identify RBPJ protein as key brake on regulatory T cells, opening path to more effective autoimmune treatments.
Summary
Researchers used genome-wide CRISPR screening to discover new regulators of FOXP3, the master gene controlling regulatory T cells that prevent autoimmune disease. They found that removing the RBPJ protein dramatically improved the stability and function of lab-grown regulatory T cells. These enhanced cells showed superior ability to suppress immune reactions in mouse models, suggesting a promising approach for developing more effective cell therapies for autoimmune conditions like multiple sclerosis and type 1 diabetes.
Detailed Summary
Regulatory T cells (Tregs) are immune system peacekeepers that prevent autoimmune disease by expressing the master transcription factor FOXP3. While scientists can create these cells in the lab for potential therapies, they often become unstable and lose their protective function, limiting clinical applications.
Researchers conducted a comprehensive CRISPR screen across the entire human genome to identify genes controlling FOXP3 expression in primary human T cells. Using advanced single-cell analysis, they systematically tested which genes, when knocked out, would enhance regulatory T cell development.
The team discovered that the RBPJ protein acts as a powerful brake on FOXP3 expression through a repressor complex with NCOR. Removing RBPJ dramatically improved regulatory T cell differentiation and stability. These enhanced cells maintained their suppressive function longer through DNA demethylation of key FOXP3 regulatory regions, essentially locking in their protective identity.
In humanized mouse models of graft-versus-host disease, RBPJ-deficient regulatory T cells showed superior therapeutic efficacy compared to standard lab-grown cells. The mechanism involves RBPJ directly suppressing FOXP3 through histone modifications, independent of traditional Notch signaling pathways.
These findings reveal new molecular targets for improving adoptive cell therapies for autoimmune diseases. By targeting RBPJ or related pathways, researchers may develop more stable and effective regulatory T cell treatments for conditions like multiple sclerosis, rheumatoid arthritis, and type 1 diabetes.
Key Findings
- RBPJ protein identified as novel negative regulator of FOXP3 expression in human T cells
- RBPJ knockout enhanced regulatory T cell stability through DNA demethylation mechanisms
- Enhanced cells showed superior therapeutic efficacy in graft-versus-host disease models
- RBPJ suppresses FOXP3 through direct histone modifications independent of Notch signaling
- Genome-wide CRISPR screen revealed multiple new regulators of regulatory T cell development
Methodology
Genome-wide CRISPR loss-of-function screen in primary human T cells with single-cell resolution analysis using Perturb-icCITE-seq. Functional validation performed in humanized mouse models of graft-versus-host disease.
Study Limitations
Study based on in vitro systems and mouse models; human clinical efficacy remains to be demonstrated. Long-term safety of RBPJ-modified cells requires further investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.